Výsledky vyhledávání - "Orlando F Bueno"

Akademický článek

Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma

Autor: Tyler J Wellman, Sarah R Mudd, Kelly N Godby, Dustin W Wooten, Jeremy A Ross, Orlando F Bueno, Danielle Wanik, Chaitanya R Divgi, Robert A Comley, Luciano J Costa, Jacob Y Hesterman

Publikováno v: Translational Oncology, Vol 37, Iss , Pp 101767- (2023)

Background: FDG PET/CT is a tool for assessing response to therapy in various cancers, and may provide an earlier biomarker of clinical response. We developed a novel semi-automated approach for analyzing FDG PET/CT images in patients with multiple m

Externí odkaz: https://doaj.org/article/c0fa07e75db04630b3f8adad4bf6cb5e

Zobrazit plný text záznamu

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Publikováno v: Blood. 140:4401-4404

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3702210848eeb438c84f70addbdd11d9
https://doi.org/10.1182/blood-2022-167008

Zobrazit plný text záznamu

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Autor: Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, Rajvineeth K. Pothacamury, Kevin J. Freise, Susan Yue, Jeremy A. Ross, Akshanth R. Polepally, Chetasi Talati, Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 31

PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d490c0a00399fe00cc257aa6c8750b
https://doi.org/10.1200/jco.22.01504

Zobrazit plný text záznamu

Data from Expanding the Repertoire for 'Large Small Molecules': Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f852ee29a9488942fba6fce73ac0eaf
https://doi.org/10.1158/1535-7163.c.6543327.v1

Zobrazit plný text záznamu

Supplementary Data from Expanding the Repertoire for 'Large Small Molecules': Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

1. Measured pKa values of ABBV-167 (Table S1. Ionization constants of ABBV-167) 2. Preparation of ABBV-167 on large scale (Scheme S1: Synopsis of GMP synthesis of ABBV-167) 3. Preparation of clinical ABBV-167 drug supply 4. Animal pharmacokinetics (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82ad084c554229baf59a8bada6e495
https://doi.org/10.1158/1535-7163.22522290

Zobrazit plný text záznamu

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Autor: David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Publikováno v: Blood. 140:4242-4244

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::451e7273da55098f80940dfe48ab9988
https://doi.org/10.1182/blood-2022-160195

Zobrazit plný text záznamu

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Autor: Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees

Publikováno v: Blood. 140:7326-7327

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b26b6feef48c5f9fe7d112391efeba8
https://doi.org/10.1182/blood-2022-157977

Zobrazit plný text záznamu

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Autor: Jonathan L. Kaufman, Nizar J. Bahlis, Jeremy A. Ross, Simon D. J. Gibbs, Yan Luo, Torben Plesner, Christine Mantis, Eva Medvedova, Philippe Moreau, Deeksha Vishwamitra, Shir-Jing Ho, Orlando F. Bueno, Annette Juul Vangsted, Hang Quach, Rachid Baz, Simon J. Harrison

Publikováno v: Bahlis, N J, Kaufman, J L, Baz, R, Quach, H, Ho, S-J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Medvedova, E, Bueno, O F, Luo, Y, Mantis, C, Vishwamitra, D, Ross, J A & Harrison, S J 2021, ' Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone ', Blood, vol. 138, no. Suppl. 1, 1633 . https://doi.org/10.1182/blood-2021-146012

Background: Venetoclax (Ven) is a highly selective, potent, oral BCL-2 inhibitor that is currently being evaluated as a targeted therapy for the treatment of t(11;14) relapsed/refractory multiple myeloma (RRMM). The combination of Ven with daratumuma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7b3429a1aff23dbdd303436f7b5654
https://portal.findresearcher.sdu.dk/da/publications/2aab7aad-040e-4740-a8b6-1754586ba081

Zobrazit plný text záznamu

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Autor: Ahmed Salem, Faith E. Davies, Andrzej Jakubowiak, Xiaoqing Yang, Wijith Munasinghe, Jeremy A. Ross, Tibor Kovacsovics, Monique Dail, Nicholas Burwick, Jonathan L. Kaufman, Edward A. Stadtmauer, Wan-Jen Hong, Gregory Monohan, Abdullah A. Masud, Orlando F. Bueno, Shaji Kumar, Luciano J. Costa

Publikováno v: Blood Adv

Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis of MM cells, and its efficacy may be pot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51b7007808126347767a475a30c4fee9
https://europepmc.org/articles/PMC8679663/

Zobrazit plný text záznamu

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Autor: Annette Juul Vangsted, Abdullah A. Masud, Jeremy A. Ross, Simon J. Harrison, Shir-Jing Ho, Torben Plesner, Hang Quach, Nizar J. Bahlis, Rachid Baz, Orlando F. Bueno, Sheryl Coppola, Xiaoqing Yang, Simon D. J. Gibbs, Jonathan L. Kaufman, Philippe Moreau

Publikováno v: Bahlis, N J, Baz, R, Harrison, S J, Quach, H, Ho, S J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Coppola, S, Yang, X, Al Masud, A, Ross, J A, Bueno, O & Kaufman, J L 2021, ' Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3602-3612 . https://doi.org/10.1200/JCO.21.00443

PURPOSE Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents inclu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60661302a7ea9152573f073b9a8edd6
https://pubmed.ncbi.nlm.nih.gov/34388020

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání